Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma
Active, not recruiting · NCT04462328 · Registry updated 2026-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | primary central nervous system lymphoma | Active, not recruiting | Phase 1 | 2026-09-16 | NCT04462328 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Washington University School of Medicine | 475 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Ohio State University Hospital | Columbus | United States | 1 |
| Washington University School of Medicine | St Louis | United States | 895 |